4D Molecular Therapeutics, Inc. (FDMT) fair value analysis
Nasdaq · Updated 2026-10-19
FDMT price how computed
Valuation status
No fair-value estimate yetFDMT has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for FDMT yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $12.14
- Sector
- Healthcare
- 12-month range
- $7.19–$16.76
- Market cap
- $671M
- From 52-week high
- -27.6%
- Shares outstanding
- 55.2M
- Rank in Healthcare by quality score
- #164 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that develops treatments for diseases of the eye, ear, and central nervous system using proprietary adeno-associated virus vectors. The company is based in the United States and conducts its research and development operations domestically.
FDMT currently ranks #164 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $671M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $92M
- Net margin
- -194.7%
- EPS (TTM)
- $-2.63
- Gross margin
- 44.8%
- Debt / equity
- 0.10
- Revenue growth (3-yr avg)
- -27.1%
- Shares outstanding
- 55.2M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 34 · neutral
- 50-day average
- $13.91
- 200-day average
- $10.65
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-09
- Last 8 quarters vs consensus
- 1 beat, 5 missed
- Quarter by quarter
- 2026-06 ▬ met (0.0%)
2026-03 ▼ miss (-1.0%)
2025-12 ▲ beat (+180.8%)
2025-09 ▼ miss (-3.1%)
2025-06 ▼ miss (-42.0%)
2025-03 ▬ met (0.0%)
2024-12 ▼ miss (-7.4%)
2024-09 ▼ miss (-12.9%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 11 buy · 1 hold · 0 sell (12 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $28.1
- Target vs last price
- +131.5%
What our data shows for FDMT
- Shares are trading in the middle of their 12-month price range of $7.19–$16.76.
- The 14-day relative strength index sits at a neutral 34.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- FDMT's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the FDMT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for FDMT show a shift in the 50/200-day trend state from uptrend to mixed as of this week. This change reflects a transition in the stock's intermediate-term momentum relative to its longer-term trajectory. The valuation verdict remains under review pending completion of the full valuation analysis.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is FDMT stock undervalued?
TickrTrends has no fair-value estimate for FDMT yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is FDMT's TickrTrends verdict?
FDMT is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does FDMT compare to other Healthcare stocks?
FDMT ranks #164 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is FDMT overbought or oversold?
FDMT's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does FDMT report earnings next?
FDMT's next earnings report is scheduled for 2026-11-09, per the published earnings calendar.
Does FDMT usually beat earnings estimates?
Over its last 8 reported quarters FDMT beat the consensus estimate 1 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about FDMT?
Of 12 analysts covering FDMT, 11 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $28.1 (+131.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.